What kind of help do you actually expect from DOV. He controls nothing other then a large block of shares. he has been fed the same BS that we have all been fed, nothing different.
No need to go back that far,you can be much more current like March 2014. I have pasted transcript portion that is relevant below
Now, let's turn to BARDA. A core priority in 2013 was completing the three deliverables for our BARDA contract
and that was accomplished on budget and ahead of schedule. Our BARDA, contract awarded in the fall of 2012,
may provide up to $106 million to fully fund the regulatory and clinical trials required by FDA to gain approval for
Cy tori solution system for the treatment of targeted soft tissue injuries. Specifically , BARDA is seeking a primary
medical countermeasure to the effects of an attack with an improvised nuclear device. In this scenario, the
nation's trauma sy stem could be overwhelmed with patients with a combined injury including radiation exposure
and thermal burns. The key benefits of this contract to Cy tori, if all options are exercised, are that, one, it provides
a fully-funded commercial path to a market that includes the world's largest customer, the U.S. government.
Second, it supports the funding and development of our next-generation Celution Sy stem; and third, it provides at
least one path through FDA for a meaningful clinical application in skin and soft tissue repair. In addition, upon
FDA approval or prior to approval in certain circumstances as deemed appropriate by BARDA, the U.S.
government has the option to purchase and deploy the Celution Sy stem as a medical countermeasure for national
preparedness. Should FDA approval be received after clinical trials, the company has the right to commercialize
its cell therapy products in accordance with the claims allowed by the FDA. The first phase or the base period of
the contract is valued at up to $4.7 million. As specified in the contract, there are three objectives in the base
period that could trigger up to $56 million in subsequent contract options. These three objectives are, one, to
validate feasibility of a next-generation sy stem; two, to demonstrate the Cy tori cell therapeutic population to be
obtained from patients with a severe burn injury; and three, to show efficacy of Cy tori cell therapy products in a
novel pre-clinical model of thermal burn within concomitant radiation exposure
Hedge while BARDA may have been 2 events, as you say ,however,that is not how it was presented. Go back and read the transcript from Q4 1013 and you will clearly see how CC presented it. Same if you go to any slide presentation , it was never broken out that way. Oh what a tangled web we weave when we practice to deceive.
hedge, sadly you have hit the nail on the head. clearly the markets are expecting bad news and in typical cytori form, shareholders will be the last to know. of course not all shreholders as some must have the heads up and have been exiting quietly and trying to salvage as much of the pps that they can. barda has gone from 56mil to 36 mil and who knows other then Cytori mangement what the final number will be and they aren't saying. the culture at cytori is dysfunctional. cc became a scapegoat and hendricks is no better. his lips move and say the right thing but just as CC, Dean, and Rickey it is all BS. Every day things look worse, as the pps continues to approach our 52 week low. Hard to believe after what was to be a milestone event BARDA has occured. Only the Cytori team can take a positive announcement and turn it completely negative. Silence can be defeaning, and the no news is good news theory surely doesn't fly when it comes to Cytori. Truely depressing.
If Llyod Dean Mr. double down ,10x's your wildest dream has yet to jump from the Golden Gate Bridge then perhaps there is a glimmer of hope, but it's fading fast. Here we sit a mere .19 above a 52 week low after what we all believed ,and were told by management was a water shed event. I find it difficult to believe this is an attempt by MM's to shake out the week hands as there will be plenty of stock available at low prices when the next wave of dilution comes with the release of thousands of new shares. If there is not major news before the annual meeting then by all accounts that event should be a blood bath. Of course it won't be as all directors will stay in place with the addition of a few more, compensation will be increased and management again will be rewarded for it's inability to perform . Our favorite whipping boy has left the building but nothing has changed,the tide has not turned and from a PPS standpoint we are worse off. This is all very confusing to me and each hour as I check the quotes hoping to see green, I only see red. I have only seen red every day now for 2 weeks. What is going to stem the tide, I sure hope that Mark Hendrik is going to shed some light on what is going on as shareholders are being kept completely in the dark. Another promise broken with regard to better communication. This really stinks and I will go into another beautiful summer weekend dreading Monday and hoping we do not drop below $2. As for KT Lim, maybe he was just in need of a tax loss.
Notice where this analyst is ranked and how well those that have followed his advise on Cytori are doing. Hate to admit they are doing better then me being down only 20%
Guess they are talking about the ability to further dilute by selling the additional shares they have been authorized to sell. Perhaps , SAAD will sell sub $2 for a quick capital raise. The way this company operates is just beyond belief.
What do you know about CC venture ? While he is stupid ,he can't be that stupid as lawsuits would be filed immediately. They will most likely sell screwing all long term holders who have supported them for 15 years. Management would of course have golden parachutes so they can continue to steal from this gravy train that has afforded them all lavish life styles at shareholder expense.
Probably not worth the paper it is printed on much like our shares but see below:
Cytori Therapeutics (CYTX - $ 2.32)
BARDA Decision is a Major Positive Development
Yesterday, CYTX reported that BARDA indicated that the agency intended to
exercise option 1 of the contract for the development of treatment for thermal burns
combined with radiation injury by CYTX.
• Details. Yesterday, CYTX reported to receive preliminary written notice from
BARDA that the agency intended to exercise option 1 of the contract for Cytori
to further develop the Celution as potential treatment for thermal burns combined
with radiation injury. The contract could extend to September 2016. Two parties
are in negotiations on the specifics of the contract and details could be available
in several weeks, possibly in August. We estimate option 1 of the contract could
worth up to $32.6MM.
• Implications. We view the success in receiving option 1 funding to further
advance Celution System development in thermal burns combined with radiation
injury is a major positive for CYTX shareholders. As such, in our opinion, the
two solid value drivers (Phase II in refractory heart failure studies and BARDA
development), now have sufficient financial backing to complete critical clinical
development and present potential major catalysts to enhance shareholder value.
CYTX earlier indicated that option 1 is the major focus of BARDA’s decision
and we believe potential of option 3 funding (~$23.4MM) is still in place. Going
forward, we anticipate reports of more detailed information regarding the
BARDA option 1 contract as near term catalyst. Investors, in our view, will
increasingly focus more on the advancement of Celution in no-option chronic
myocardial ischemia Phase II developments (ATHENA), which include 1)
potential patient recruitment completion in 4Q14; and 2) potential top-line results
release in mid-15 or 3Q15. Another point of focus includes continued
advancement of the ATHENA II study with top-line results available possibly in
2H15. In addition, additional commercial (especially from Japan) and clinical
developments of Celution as well as potential approval and subsequent
commercialization in China possibly start in late 2014 also are catalysts for
• Action. We have tweaked our financial projection with 2Q - 4Q14 net losses to
($0.15), ($0.10) and ($0.06) from ($0.09), ($0.09) and ($0.04), respectively. We
reiterate our Buy rating and our $9 target price based on our peer comparison
valuation methodology and by our risk-adjusted cash flow sum-of-the-parts
analysis for ADRCs in no option CMI
Cytxer, Agree on numerous points however, there is nobody on this board that expected a negative move in PPS on BARDA approval. Those that consider themselves to be experts were predicitng $3.25 and while that was wishful thinking you could not have possibly expected a negative move on the PPS. When it comes to filing of patents of course that stays internal . Thinking from your posts that you could not possibly be holding this stock more then a few months, no way you are long term holder as you would surely have a better grasp of the situation. CC was in Europe prior to his leaving to work on getting partnership I assume related to sports medicine and what exactly to do we have to show for it. When you were doing your DD you should have learned of all the mis steps, do overs , mistakes to not understanding of protocal that this management team has made and continues to make. It is not at all surprising that the PPS sits where it does. While many including myself believe in the potential of Cytori potential partners surely know more then we do and there is nobody stepping up to the bar other then the mysterious Mr. Lim. are you not the least bit curious about what is going on here considering this was to be a deal that down the road was expected to generate royalties over 500 million. What about Japan who passed legislation many months ago but have yet to generate a partnership or meaningful revenue or sales that may generate revenue at a much later date due to SAAD's use of mumbo jumbo accounting. CYTX has been in Japan and supposedly has the best relationships with business and government of any company in the field yet nothing but ,broken promises, shattered dreams and losses is all that we have to show for it. July 31 will be very interesting and I hope management will be forthcoming.
John "It seems to me that they have been working on a lot of things we know nothing about" and therein lies the problem. Communication stinks. Rickey and Hendrik both have made points as recently as the last conference all that they will focus on keeping shareholders informed. They are failing miserably. Let's face it, we have more information when betting a football game then we have from Cytori and we have a lot more invested here. Actions speak louder then words and you are only guessing at what is going on. You do not know. I you knew then you would not be underwater on this investment. The corporate culture at Cytori ,stinks and shareholders should not be kept in the dark. This is not going to change and as you see from the PPS that there is a HUGE credibility problem and we remain in the dark. management is asking shareholders to trust them and put faith in them, that is earned not given. We have given them the benefit of the doubt for years, myself going on 5 and I have nothing but huge losses to show for it. Things should be getting better but the ship is taking on water.
Market responds 2 consecutive days with losses on CYTX after what would appear to be positive news, BARDA and another patent. Completely baffled . Perhaps low priced secondary, with more dilution coming shortly. CYTX can never seem to get out of it's own way.
street while stem cells may very well be viable in treating hamstrings,as well improving recovery from orthopedic surgeries as Dr's believe ,you can't be suggesting this is a miracle cure or is txer mis interpreting your point?
As letter of intent is not binding then perhaps based on history there remains a question. Always a chance of reduced funding or decision not to move forward, however, that just seems so unlikely. maybe good news on a bad day contributing. Volume close to 700,000 share @ 2:30 pm, perhaps a very controlled short covering. Don't think longs like us are ready to commit more $'s when so many of us feel we are over invested as it is. News is positive for sure but this is Cytori and the company is still in need of cash as this award is quite focused as to where monies will be spent. Wonder what's up with KT. Surely we will learn more on the 31st of this month.
Agree VC , congratulations are in order. Step in right direction. No bullish sentiment until $'s and terms are released which will be another 2 weeks. I expect that means annocement day before anual meeting July 31 and more color then. Hope the $'s don't disappoint which could put a damper on this news which is a positive, for sure.
The letter was sent on June 16 which is even more troublesome. Just can't believe anything that anyone at Cytori says. CC could not mange expectations and now Hendrik is no better. Just completely frustrating. I did write to Meg a couple weeks ago and while she is usually quick to reply within a day,not a word. Can you blame her, she has nothing to report. With shareholder meeting on the 31,I am sure that there is much shareholders want to know,but most who post here a re pumpers who do not want to hear anything but having smoke blow up there #$%$
Are you still planing on treating patients in august or is that timeline as accurate as BARDA timeline, as you are already a year late. Of course nothing involving Cytori ever goes as planned. Hoping that Okyanos is a success and treats many patients, that cellution machines work well,and many consumables will be purchased. Clyde Shores needs some purchases to boost his pathetic sales numbers.
Sad but oh so true,but again definition of insanity is to keep doing the same thing over and over and expecting a different result. To date the worst investment I have ever made, and the last one in this market that is controlled by programed selling. Can't blame the computers here just the mangement team at Cytori and myself for being so F'n stupid.